South Korea finds illegal GLP-1 sales at six clinics

South Korea’s Ministry of Food and Drug Safety said on May 13 that six of 632 clinics and pharmacies inspected with local governments had violated medical or pharmaceutical rules tied to GLP-1 obesity drugs. The inspections targeted sites that had received tirzepatide injections, the ingredient in Eli Lilly’s Mounjaro, according to KoreaBioMed. The ministry said inspectors compared wholesale supply records with clinic and pharmacy inventory records and checked whether prescription-only drugs had been sold or dispensed without prescriptions. ### Which regulator found the violations, and when? South Korea’s Ministry of Food and Drug Safety, or MFDS, announced the findings on May 13 after a joint inspection with local governments, KoreaBioMed reported. LucidQuest Ventures cited the same MFDS action in its May 19 obesity-market roundup, saying the case highlighted compliance issues in the country’s fast-growing obesity-drug market. The number at the center of the inspection was 632. (koreabiomed.com) Out of those 632 clinics and pharmacies, six were found to have violated relevant rules, according to MFDS as quoted by KoreaBioMed and Dongascience. ### What exactly did inspectors say the clinics and pharmacies did? Inspectors checked whether prescription-only GLP-1 medicines had been sold or dispensed without prescriptions, KoreaBioMed reported. (koreabiomed.com) MFDS also reviewed whether inventory records at clinics and pharmacies matched wholesale distribution records for the drugs. Two clinics were found to have cases in which doctors used GLP-1 obesity drugs on themselves without creating medical records, the ministry said, according to KoreaBioMed. (koreabiomed.com) Dongascience’s English report said the violations included illegal distribution and failures in record-keeping. ### Which drugs were involved? Tirzepatide was the main focus of the inspection, according to KoreaBioMed, which said the checks centered on sites that had received tirzepatide injections. (koreabiomed.com) Tirzepatide is the active ingredient in Eli Lilly’s Mounjaro. LucidQuest’s May 19 briefing framed the issue more broadly as involving GLP-1 obesity drugs, including semaglutide and tirzepatide distribution practices. (koreabiomed.com) That characterization appears to be an inference from the broader obesity-drug market rather than a direct MFDS list of every product inspected; the primary reported inspection target was tirzepatide-handling sites. ### Why were regulators checking these sites now? (koreabiomed.com) MFDS carried out the inspection as demand for injectable obesity drugs expanded in South Korea, according to KoreaBioMed and LucidQuest. LucidQuest said the case could affect prescriber choice and payer reviews pending fuller data, though that assessment was LucidQuest’s interpretation rather than a statement from MFDS. The ministry’s inspection method was specific: officials compared supply-chain records against on-site stock and checked prescription compliance. (lqventures.com) That suggests the review was aimed at distribution controls as much as at clinical use. This is an inference based on the inspection steps described by KoreaBioMed. ### Where did this report first surface in English? KoreaBioMed published an English-language report on May 14 summarizing the MFDS findings. (lqventures.com) Dongascience also published an English report last week stating that six of 632 inspected locations were found in violation. LucidQuest Ventures then included the case in its “Obesity Today—May 19, 2026” briefing. That note linked the Korean inspection to wider safety and compliance concerns in the obesity-drug market. (koreabiomed.com) ### What happens next? The next public reference point is likely to be any follow-up notice from South Korea’s MFDS or additional local reporting on enforcement actions against the six sites. As of the May 14 KoreaBioMed report and the May 19 LucidQuest briefing, the disclosed facts were the 632 inspections, the six violations, and the specific issues involving prescription handling and medical records. (koreabiomed.com) (lqventures.com)